Developing a vaccine to combat antibiotic-resistant E. coli infections
Official title: ExPEC Vaccine Development
Funded at Baylor College of Medicine · NIH-11125016 · Data updated 2026-11-12
This study is working on a new vaccine to help protect people from serious infections caused by a harmful type of E. coli that can lead to antibiotic resistance, and it aims to find a way to keep you safe from these infections in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | August 15, 2024 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $400,000 |
| NIH project number | 1R56AI177630-01A1 |
| Project ID | NIH-11125016 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk for infections caused by antibiotic-resistant bacteria, particularly those with compromised immune systems or underlying health conditions.
✕Less likely to help
Patients who are not at risk for infections caused by E. coli or those who do not have underlying health conditions may not benefit from this research.
What this research studies
This research focuses on creating a vaccine to protect against extraintestinal pathogenic E. coli (ExPEC), a major cause of antibiotic resistance and related mortality. By analyzing over 20,000 strains of this bacterium, researchers have identified key virulence factors that could be targeted for vaccine development. The project will involve pre-clinical studies to test the vaccine's effectiveness in preventing various types of ExPEC infections, optimizing vaccine parameters, and exploring innovative adjuvants to enhance immune response. Patients may benefit from a new preventive measure against serious infections caused by this dangerous pathogen.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence of life-threatening infections caused by antibiotic-resistant E. coli.
How similar studies have gone: Previous research has shown promise in developing vaccines targeting antibiotic-resistant bacteria, indicating potential for success in this novel approach.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Maresso, Anthony W — Baylor College of Medicine
- Study coordinator: Maresso, Anthony W
Related research
Other NIH-funded projects on the same topics.
-
Multimodal AI to improve genetic diagnosis of congenital heart disease
A new AI tool uses multiple types of patient data to help doctors find genetic causes of congenital heart disease more accurately.
-
Surveillance of Vaccine-Preventable Diseases in Children
This project watches how often common vaccines prevent illnesses in kids who are in the hospital or at the emergency department, and compares them with healthy children getting well-child care.
-
Triple gene therapy approach to heal the heart after a heart attack
A new therapy combines three genetic approaches delivered by a virus to help the heart heal after a heart attack.
-
Thalamic sleep circuit changes in Alzheimer's disease
Aims to understand how sleep-related brain activity in a key sleep regulator called the TRN affects Alzheimer’s progression and whether boosting TRN function could slow symptoms.
-
Cardiomyocyte-fibroblast signaling in atrial fibrillation
A researcher at Baylor College of Medicine is studying how signals between heart muscle cells and supportive heart cells influence atrial fibrillation, with the goal of finding new ways to prevent or treat this common heart rhythm problem.
-
UMPIRE: Keeping Kidneys Healthy for Babies with Spina Bifida
A care protocol for newborns with spina bifida aims to protect kidney function by thoughtful bladder management and monitoring from birth.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.